SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is gaining traction as a privacy-focused layer-1 blockchain, with recent partnerships sparking increased interest and bullish sentiment. The community is highlighting its focus on regulatory compliance and real-world utility, differentiating it from hype-driven projects. Some users are drawing comparisons to ZCash ($ZEC) and anticipating significant growth potential.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is gaining traction as community members highlight its growing user base, surpassing Solana and Ethereum in active users, which may be driving the current rally. Bullish sentiment is also fueled by discussions around AI integration and staking opportunities within the NEAR ecosystem. Traders are actively monitoring potential breakout setups and key price levels.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is trending as investors analyze recent stock transfers by the CEO to family trusts, speculating about potential buyout negotiations. The community is weighing the company's fundamentals, revenue growth, and potential catalysts like subq treatment data, with some expressing frustration over long-term returns and perceived market manipulation. Bullish sentiment persists due to Briumvi's market performance and potential, while bearish voices cite concerns about drug pricing and overall market conditions.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax ($KMX) is trending as the stock experiences volatility following CEO Bill Nash's resignation and a disappointing sales forecast, leading to community debate about the company's future and potential undervaluation. Some investors are weighing whether it's a buying opportunity, while others express concerns about subprime lending risks and comparisons to competitor Carvana. Analyst ratings are mixed, with some lowering price targets.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending amid increasing community excitement around its potential in Sovereign AI and growing partnerships with major tech companies like Microsoft. Discussions center on the transformative potential of government and sovereign AI contracts, particularly in the Middle East, with institutions potentially viewing INOD as the next Nvidia. The community speculates on substantial revenue growth and a shift in business direction, from tech to government and AI.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin CAW (crow with knife) is trending as the community rallies around its fully circulated, multichain tokenomics and active development team. Conversations highlight its presence on Solana, Base, and other chains, with users emphasizing its strong community and deflationary burn mechanism. Community members are actively using the project's slogan 'caw caw caw'.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following segments: North America, Europe, Middle East and Africa (EMEA), Latin America, and Asia. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is trending amid community discussion around its valuation and potential triggers, including a possible Supreme Court ruling on tariffs and the progress of the Whirlpool of India divestment. Investors are weighing the impact of short positions, dividend prospects, and technical indicators like hammer candlesticks and rounded bottoms. Options activity and potential for a short squeeze are also being actively monitored.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology ($STX) is trending as investors assess its potential in the AI-driven data storage market, with Bernstein upgrading the stock. Community discussions revolve around the sustainability of the memory and hard drive sector's gains, particularly compared to other tech stocks. Some traders point to technical indicators suggesting it may be overbought, while others highlight factors such as strong earnings and fund support.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

BSX is trending due to positive momentum in their electrophysiology and cardiovascular segments, prompting several analysts to raise price targets. The community is also discussing potential acquisitions and key resistance levels, with many noting the stock's consistent upward trend and strong technical setup. However, some are expressing concern about potential short-term pullbacks and recent insider selling.

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

FDMT is trending due to positive 60-week data from its 4D-150 program in DME, sparking renewed investor interest and heavy trading volume. The community is discussing the potential for a short squeeze and analysts' high price targets, while also considering the possibility of a partnership or buyout. Attention is focused on the company's strong cash position and the acceleration of its Phase 3 trial for wet AMD.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chardan Capital Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Chardan Capital reduced their price target on Intellia Therapeutics from $48.00 to $26.00 and set a "buy" rating on the stock in a research report on Friday...

Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $12.00 at Wells Fargo & Company

Wells Fargo & Company dropped their price target on Intellia Therapeutics from $17.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Friday...

Royal Bank Of Canada Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Royal Bank Of Canada dropped their target price on Intellia Therapeutics from $14.00 to $9.00 and set a "sector perform" rating on the stock in a research report on Friday...

Barclays Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $14.00

Barclays decreased their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an "overweight" rating for the company in a report on Friday...

Intellia Therapeutics (NASDAQ:NTLA) Given New $7.00 Price Target at Wedbush

Wedbush reduced their target price on shares of Intellia Therapeutics from $9.00 to $7.00 and set a "neutral" rating on the stock in a report on Friday...

Citizens Jmp Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $21.00

Citizens Jmp decreased their price objective on shares of Intellia Therapeutics from $29.00 to $21.00 and set a "market outperform" rating for the company in a report on Friday...

Intellia Therapeutics' (NTLA) "Underweight" Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $5.00 target price (down previously from $12.00) on shares of Intellia Therapeutics in a research report on Friday...

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down Following Analyst Downgrade

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Down After Analyst Downgrade...

Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.10 EPS

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts...

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$9.52
Prev Close	$12.32
Open	$9.15
Dividend Yield	0.00%
50-Day Moving Average	$17.19
Beta	1.72
Avg. Volume	10.01M
PE Ratio	-2.03

52-Week High	$28.25
52-Week Low	$5.90
Market Capitalization	$1.02B
EPS (Annual)	-$5.25
Price to Book	1.40
Revenue Per Employee	$143,615.39
Enterprise Value/EBITDA	N/A

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News

NTLAIntellia Therapeutics Inc